AstraZeneca (LON:AZN - Get Free Report) had its price objective boosted by Berenberg Bank from £142 to £145 in a research note issued to investors on Tuesday,Digital Look reports. The brokerage currently has a "buy" rating on the biopharmaceutical company's stock. Berenberg Bank's price objective points to a potential upside of 15.65% from the company's previous close.
AZN has been the topic of several other research reports. Shore Capital reissued a "buy" rating and set a £145 price objective on shares of AstraZeneca in a research note on Tuesday, October 7th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and issued a £110 price objective on shares of AstraZeneca in a research note on Wednesday, July 30th. Finally, JPMorgan Chase & Co. restated an "overweight" rating on shares of AstraZeneca in a report on Monday, October 13th. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of £135.
View Our Latest Stock Analysis on AZN
AstraZeneca Price Performance
AZN stock traded up GBX 64 during trading on Tuesday, hitting £125.38. The stock had a trading volume of 33,128,629 shares, compared to its average volume of 12,456,634. The stock has a market cap of £194.37 billion, a price-to-earnings ratio of 23.61, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The company has a debt-to-equity ratio of 73.83, a quick ratio of 0.59 and a current ratio of 0.93. The company's 50 day moving average price is £119.63 and its two-hundred day moving average price is £110.08. AstraZeneca has a 1-year low of GBX 9,573.51 and a 1-year high of £129.72.
Insiders Place Their Bets
In other AstraZeneca news, insider Aradhana Sarin sold 9,563 shares of the stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of £115.12, for a total value of £1,100,892.56. 0.14% of the stock is currently owned by corporate insiders.
About AstraZeneca
(
Get Free Report)
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
